Seattle and South San-Francisco based preclinical biotech company Sonoma Biotherapeutics has raised $265 million in new funding, the company announced Wednesday. The funding will be used to advance its programs… Read More
The age of molecular-scale computing is entering a new era, thanks to the development of a system that uses synthetic proteins and Boolean logic to identify cancer cells. The proteins… Read More
Researchers at Seattle’s Fred Hutchinson Cancer Research Center have demonstrated the effectiveness of a new method for getting immune cells to fight solid tumors — by spreading them like jam… Read More
Maryn Sage remembers the words she heard on the day she learned that her 16-year-old son, Jedd Feliciano, was cancer-free. “His marrow’s clean,” the doctor told her over the phone,… Read More
Two months after Merck acquired Seattle-based biotech Immune Design for $300 million, the president of Merck Research Laboratories, Roger Perlmutter, says the city’s life science community has plenty more to… Read More
BELLEVUE, Wash. — Cancer treatments have improved astronomically in the past few decades. But as more patients overcome the disease, a different monster is rearing its head: financial toxicity. “Most… Read More
The emerging form of cancer treatment called CAR T immunotherapy is wiping out the disease in some terminal patients — but despite early successes, the treatments still have major drawbacks. Many… Read More
Nearly 40 years ago, scientists had what seemed like a crazy idea: What if we could reprogram cancer patients’ immune systems to wipe out their disease? It turns out the… Read More
Seattle Children’s Research Institute is launching a clinical trial that will examine a new kind of cancer-fighting treatment. The treatment is a type of CAR T immunotherapy, which reprograms a… Read More
CAR T immunotherapies are one of the hottest topics of research — and investment — in the world of medicine today. The emerging treatments have had shocking success in the past few years,… Read More
When Avery Berg was diagnosed with aggressive, late-stage brain cancer at just 10 years old, she fought hard to stay positive and beat the disease with a smile. “I didn’t… Read More
New cancer immunotherapies could revolutionize how we treat the disease, but for many children, those treatments are far out of reach. A new collaboration between four children’s hospitals across North… Read More
When scientists at Seattle Children’s Research Institute began studying a new immunotherapy cancer treatment a few years ago, they found stunning results. More than 90 percent of children with leukemia… Read More
Juno Therapeutics, the Seattle-based biotech company developing immunotherapy cancer treatments, unveiled promising new data from a study on its flagship cancer drug Wednesday. The company also beat analyst expectations with… Read More
CAR T immunotherapies — which genetically program immune cells to fight cancer — hold incredible promise for cancer patients who have run out of other options. But the treatments also… Read More
When you walk into Juno Therapeutics‘ new headquarters in Seattle, your eyes are immediately drawn to the view. The office’s 12th-floor reception desk offers a stunning panorama of the Olympic mountains,… Read More
A new immunotherapy technology developed at Seattle’s Fred Hutchinson Cancer Research Center has been licensed to New York-based Mustang Bio, a subsidiary of Fortress Biotech. The technology is the basis… Read More
The Food and Drug Administration announced Wednesday that it has approved the first CAR T immunotherapy in the United States, a huge milestone for the group of breakthrough cancer treatments.… Read More
Seattle-based biotech company Juno Therapeutics beat analyst expectations in its second quarter revenue Thursday, reporting $21.3 million in revenue for the quarter compared to an analyst estimate of $15.82 million.… Read More